Aβ42 oligomers drive TDP-43 phosphorylation at s409/410 through CDK5/p25 activation specifically in AD, generating a phospho-signature distinct from ALS/FTLD
TDP-43 inclusions occur in AD, ALS, and FTLD but the pathogenic mechanisms leading to TDP-43 pathology may differ between diseases. Understanding disease-specific drivers could reveal why TDP-43 shows limbic distribution in AD versus other patterns in ALS/FTLD.
Gap type: unexplained_observation
Source paper: TDP-43 Pathology in Alzheimer's Disease. (2021, Mol Neurodegener, PMID:34930382)
Aβ42 oligomers preferentially accumulate in limbic regions where they hyperactivate CDK5/p25, leading to pathological phosphorylation of TDP-43 at serines 409/410. This creates AD-specific phospho-epitopes that promote cytoplasmic aggregation while impairing nuclear import. The SKEPTIC raises valid concerns about CDK5's ubiquitous expression lacking regional specificity and cites LATE-NC evidence showing TDP-43 can aggregate independently of Aβ. The DOMAIN_EXPERT confirms CDK5 is a validated kinase with existing inhibitor chemotypes but notes CDK5 has ~300 known substrates and prior inhibitor trials failed due to toxicity, with CDK5 knockout being embryonic lethal.
...
Aβ42 oligomers preferentially accumulate in limbic regions where they hyperactivate CDK5/p25, leading to pathological phosphorylation of TDP-43 at serines 409/410. This creates AD-specific phospho-epitopes that promote cytoplasmic aggregation while impairing nuclear import. The SKEPTIC raises valid concerns about CDK5's ubiquitous expression lacking regional specificity and cites LATE-NC evidence showing TDP-43 can aggregate independently of Aβ. The DOMAIN_EXPERT confirms CDK5 is a validated kinase with existing inhibitor chemotypes but notes CDK5 has ~300 known substrates and prior inhibitor trials failed due to toxicity, with CDK5 knockout being embryonic lethal. Phosphoproteomics comparing AD-TDP cases with LATE-NC and primary FTLD could resolve whether AD-specific kinase involvement exists.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
MECH 4CLIN 1GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Aβ42 treatment of neurons induces CDK5-dependent T…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-21 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: Disease-Specific TDP-43 Pathology in AD vs. ALS/FTLD
Hypothesis 1: Amyloid-β Oligomer–Mediated TDP-43 Phosphorylation at AD-Specific Residues
Title: Aβ42 oligomers drive TDP-43 phosphorylation at s409/410 through CDK5/p25 activation specifically in AD, generating a phospho-signature distinct from ALS/FTLD
Mechanism: Aβ42 oligomers preferentially accumulate in limbic regions (hippocampus, amygdala) where they hyperactivate CDK5/p25, leading to pathological phosphorylation of TDP-43 at serines 409/410. This creates AD-specific phospho-epitopes that pr
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of TDP-43 Pathology Hypotheses
| Issue | Problem | |-------|---------| | Specificity paradox | CDK5 is ubiquitously expressed in neurons. If Aβ42→CDK5→pTDP-43 is the mechanism, why don't motor neurons with any Aβ exposure show limbic-pattern pathology? The hypothesis lacks a cell-type-specific amplifier explaining regional susceptibility. | | Causality ambiguity | Aβ42-induced CDK5 activation (PMID 28794024) may represent general proteostatic stress response, not a specific pathogenic
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
| Domain | Assessment | Notes | |--------|-------------|-------| | Druggability | Moderate–High | CDK5 is a validated kinase with existing inhibitor chemotypes (roscovitine derivatives, dinaciclib). However, CDK5 has ~300 known substrates; achieving selective TDP-43 phosphorylation inhibition without disrupting neuronal cytoskeleton or synaptic function is challenging. indirect targeting via Aβ42 reduction (anti-amyloid antibodies) could achieve
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "Aβ42 oligomers drive TDP-43 phosphorylation at s409/410 through CDK5/p25 activation specifically in AD, generating a phospho-signature distinct from ALS/FTLD", "description": "Aβ42 oligomers preferentially accumulate in limbic regions where they hyperactivate CDK5/p25, leading to pathological phosphorylation of TDP-43 at serines 409/410. This creates AD-specific phospho-epitopes that promote cytoplasmic aggregation while impairing nuclear import. The SKEPTIC raises valid concerns about CDK5's ubiquitous expression lacking regional specific